SAN FRANCISCO, Jan. 29, 2019 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the fourth quarter and full year 2018 after the close of trading on Tuesday, February 12, […]
Other News
Medtronic Valiant(TM) Captivia(TM) Demonstrates Durability, Safety, and Efficacy at Five Years in Transection Patients
DUBLIN and SAN DIEGO – January 30, 2019 – Medtronic plc (NYSE:MDT) today announced new data supporting the long-term durability, safety, and efficacy of the Valiant(TM) Captivia(TM) thoracic stent graft system for the treatment of blunt thoracic aortic injury (BTAI). The presentation by Himanshu J. Patel, M.D., University of Michigan Department […]
First-time Data Unveiled at the 31st Annual International Symposium on Endovascular Therapy
HOLLYWOOD, Fla., Jan. 29, 2019 /PRNewswire/ — The International Symposium on Endovascular Therapy (ISET), today announced that more than 20 highly anticipated research studies, including the first-time presentation of data from a promising clinical research trial, were presented during this year’s meeting, January 27-30 at The Diplomat Hotel in Hollywood, Florida. Below is a summary from […]
Neovasc Announces Renewal of German NUB Status 1 Designation for Neovasc Reducer™ Procedure for Treatment of Refractory Angina
VANCOUVER, Jan. 30, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the “Institut für das Entgeltsystem im Krankenhaus” (“InEk”), the […]
Baylis Strengthens Global Commercialization Strategy with Senior Hire
TORONTO, Jan. 30, 2019 /PRNewswire/ – Baylis Medical is pleased to announce that seasoned marketing executive Gloria Yee has joined Baylis as its Vice President of Marketing. In her role, Gloria will be instrumental in expanding the company’s global commercialization strategy. “We are thrilled to welcome Gloria to Baylis,” said Baylis President Kris Shah. “Her demonstrated […]
Cardiovascular Disease Deaths May Double In U.S. By 2040 If New Treatment Innovations Are Not Discovered, Utilized
BEVERLY HILLS, Calif., Jan. 29, 2019 /PRNewswire/ — Without new treatment options and greater utilization of current cholesterol lowering therapies, the mortality rate from cardiovascular disease (CVD) could increase 62 percent by 2040, according to a study published in the January issue of Clinical Cardiology. While deaths due to CVD have declined over the past 50 years due to improved management […]
S4 Medical Completes Successful Development Study
CLEVELAND, Jan. 29, 2019 /PRNewswire/ — Recently renamed medical device company, S4 Medical, successfully completed its milestone development study, which demonstrated capability of protecting the esophagus from thermal damage during catheter ablation. Catheter ablation is an effective treatment for patients with atrial fibrillation (AF), but carries risk of esophageal injury due to […]
Medicure Announces Agreement to Market ReDS™ Device for Congestive Heart Failure Patients in the United States
WINNIPEG, Jan. 28, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV:MPH,OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce it has entered into an agreement with Sensible Medical Innovations Inc. (“Sensible”) to become the exclusive marketing partner for the ReDS™ point of care system (“ReDS”) in the United States. ReDS is […]
Medtech Company Perfuze Raises €3 Million in Seed Round
GALWAY, Ireland–(BUSINESS WIRE)–Perfuze, a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, has closed a €3 million seed investment round. The funding facilitates the further development of the Millipede platform technology. According to WHO, stroke is the second leading global cause of death and a leading […]
Neovasc Receives Approval to Proceed with Phase 2 of TIARA-II Study from Clinical Regulators in Germany and the UK
VANCOUVER, Jan 29, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it has completed the Phase 1 requirements of the […]



